Checkmate Capital
VC Fund
Pasadena, United States
Checkmate Capital is a VC fund in Pasadena focused on Biotechnology and Health Care. The diverse experience of the Checkmate Capital team allows us to invest confidently across a range of industries including bio tech, ag tech, waste and energy.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 90%
Last updated:
For AI agents: llms.txt
Industries Checkmate Capital invests in
Stages Checkmate Capital invests in
Countries Checkmate Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 7 (70%)
- Health Care 2 (20%)
- Medical Device 2 (20%)
- Pharmaceutical 2 (20%)
- Medical 1 (10%)
Stage
- Seed 4 (40%)
- Series A 2 (20%)
- Pre-Seed 1 (10%)
- Series B 1 (10%)
- Convertible Note 1 (10%)
Country
- United States 8 (80%)
- South Korea 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Scott Shaw
Managing Director & Partner
|
Managing Director & Partner | Total investments: 0 | Find email | |
Tom Paschall
Chief Executive Officer
|
Chief Executive Officer | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NeuroSigma
|
NeuroSigma, Inc. is a medical device company based in Westwood, California. NeuroSigma is focused on commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD).NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I, II, & III clinical trials. | $1M / Venture - Series Unknown / Dec 15, 2025 | |
Bredis
|
Bredis is a technology company that provides medical device technology commercialization, research, and development. | Seed / May 19, 2023 | |
Lynx Biosciences
|
LynxBiosciencesis a clinical-stage biotechnology company focused on transforming the development of blood cancer therapies and delivering precise patient management by identifying the most promising therapeutic options. It is combining physiologically relevant suspension cell co-culture assays, automated microfluidics, and deep learning analyticswith the goal of rapidly advancing drug candidates in oncology and bringing personalized cancer treatments to patients. | Seed / Nov 03, 2021 | |
MAIA Biotechnology
|
MAIA Biotechnology is an immuno-oncology company that focuses on developing first-in-class drugs with novel mechanisms. | $8M / Convertible Note / May 19, 2021 | |
Elucid
|
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from asingle CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services. | $10M / Series A / May 10, 2021 | |
Lactiga
|
Lactiga is an award-winning, venture-backed biotherapeutics company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk to battle even the world’s most dangerous pathogens. | $1.4M / Seed / Dec 01, 2020 | |
|
Lactiga
|
Lactiga is an award-winning, venture-backed biotherapeutics company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk to battle even the world’s most dangerous pathogens. | $1.4M / Pre-Seed / Dec 01, 2020 | |
Monarch Biosciences
|
MonarchBio is a Los Angeles-based biotechnology company focused on local delivery of cell therapies for treating solid tumors. MonarchBio's unique thin-film bio | $1M / Seed / Apr 08, 2020 | |
SiteFuel
|
SiteFuel team committed to a pretty high bar and they have not let us down. They needed a solution where they could make a single phone call have someone else manage the process for us. They have dozens of jobsites with their specialty equipment onsite and these need to stay up and running. SiteFuel has been able to get us fuel on-time, where theyneed it, using several suppliers, and without missing a beat. Great job They have thousands of units nationwide and the nature of the technology means that they cannot be without fuel to power their sites. SiteFuel has delivered for us time and time again, even in hard to reach places. They call them and they connect the dots | $5M / Series A / Apr 25, 2018 | |
TELA Bio
|
TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. | Series B / Apr 16, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Checkmate Capital invest in?
Checkmate Capital invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Checkmate Capital?
Public channels for Checkmate Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Checkmate Capital?
The team at Checkmate Capital includes Scott Shaw (Managing Director & Partner) and Tom Paschall (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
